Transcript:

Exodus is the right solution at a critical time in the History of Hip and Knee Arthroplasty revision surgery, 

Revision surgeries are increasing exponentially, and there’s not enough surgeons to meet the demand.

Surgeons will have to be more efficient

Post-pandemic joint replacements immediately returned to their pre-pandemic pace in 2021 and grew even more from deferred elective surgeries and will continue as the target population expands.

Exodus offers patented differentiated solutions to help surgeons be more efficient in both hospital and ASC surgical settings.

Exodus has continued to grow since its official launch in 2019, 

with a distribution agreement in place, Exodus has scaled rapidly and is on pace for five million in revenue this year.. 

Given the growing demand,  Exodus Expects a compound annual growth rate of 40%, growing annual revenue from 9M next year to 35 Million in year 5

with the potential for greater than 90% margins on recurring attachment sales.

There is a groundswell of market need coming and only with solutions like Exodus can we solve these problems. 

Exodus: Designed for revisions. Designed for surgeons.